SCHEMBL15071485

SCHEMBL15071485

O=P(O)(O)OC[C@H]1OC(n2cnc3c(Cl)ccnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 3/20 0.70
TAS1R1 Q7RTX1 3/20 0.70
DNPH1 O43598 14/20 0.67
PRKAB2 O43741 1/20 0.67
TRPM2 O94759 1/20 0.67
LDHA P00338 1/20 0.67
ADRB2 P07550 1/20 0.67
FBP1 P09467 1/20 0.67
SRC P12931 1/20 0.67
ADORA1 P30542 1/20 0.67
P2RY2 P41231 1/20 0.67
P2RY1 P47900 1/20 0.67
PRKAG1 P54619 1/20 0.67
PRKAA2 P54646 1/20 0.67
PDE4D Q08499 1/20 0.67
KCNH2 Q12809 1/20 0.67
PRKAA1 Q13131 1/20 0.67
PDE3A Q14432 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
P2RY11 Q96G91 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15248804 1.00 TAS1R3 (0.70) TAS1R3TAS1R1DNPH1PRKAB2TRPM2
SCHEMBL14928618 1.00 TAS1R3 (0.70) TAS1R3TAS1R1DNPH1PRKAB2TRPM2
SCHEMBL14946171 0.91 P2RX3 (0.73) TRPM2SRCP2RY2P2RY1SMN1; SMN2
SCHEMBL14928636 0.88 DNPH1 (0.73) TAS1R3TAS1R1DNPH1PRKAB2TRPM2
SCHEMBL15249230 0.88 DNPH1 (0.73) TAS1R3TAS1R1DNPH1PRKAB2TRPM2
SCHEMBL14928846 0.85 TAS1R3 (0.67) TAS1R3TAS1R1DNPH1PRKAB2TRPM2
SCHEMBL15248807 0.85 TAS1R3 (0.67) TAS1R3TAS1R1DNPH1PRKAB2TRPM2
SCHEMBL15071492 0.85 TAS1R3 (0.67) TAS1R3TAS1R1DNPH1PRKAB2TRPM2
SCHEMBL20282659 0.84 DNPH1 (0.77) TAS1R3TAS1R1DNPH1PRKAB2TRPM2
SCHEMBL622623 0.84 DNPH1 (0.77) TAS1R3TAS1R1DNPH1PRKAB2TRPM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9149506-B2 Modified polynucleotides encoding septin-4 MODERNA THERAPEUTICS, INC. (US) 2015-10-06 US disclosed
US-20140141067-A1 MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 MODERNA THERAPEUTICS, INC. (US) 2014-05-22 US disclosed
US-20130165504-A1 METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT modeRNA Therapeutics (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140141067-A1 MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 SEPTIN7, SEPTIN9, SEPTIN8 TAS1R3 4408/4885TAS1R1 4485/4885DNPH1 2995/4885
US-20130165504-A1 METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT RNGTT, L3MBTL3, RNASE1 TAS1R3 4077/4885TAS1R1 4219/4885DNPH1 3312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.